In This Article:
Checkpoint Therapeutics (NASDAQ:CKPT) Third Quarter 2024 Results
Key Financial Results
-
Net loss: US$9.73m (loss widened by 70% from 3Q 2023).
-
US$0.23 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Checkpoint Therapeutics Earnings Insights
Looking ahead, revenue growth is forecast to be higher than the Biotechs industry in the US during the next 2 years.
Performance of the American Biotechs industry.
The company's shares are up 9.2% from a week ago.
Risk Analysis
It is worth noting though that we have found 5 warning signs for Checkpoint Therapeutics (4 are a bit unpleasant!) that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.